In OI patients’ cultures with MCSF and RANKL, a double effect can be observed: there is a significant decrease in CK-BB levels at 1 μmol/L neridronate compared with the control condition without neridronate (p = 0.03), whereas at 3 μmol/L neridronate the highest levels of CK-BB can be detected with respect to the control without neridronate (p < 0.04) and to 1 μmol/L neridronate (p = 0.03). The gene discussed is TNFSF11; the disease is osteogenesis imperfecta.